Threshold Pharmaceuticals (THLD) saw its loss narrow to $5.70 million, or $0.08 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $6.43 million, or $0.09 a share.
The company has not recorded any revenues for the current quarter. However, it has reported a revenue of $3.68 million for the previous year period.
Operating loss for the quarter was $5.24 million, compared with an operating loss of $6.77 million in the previous year period.
"We plan to initiate a clinical trial evaluating evofosfamide in combination with checkpoint inhibitors with our collaborators at MD Anderson Cancer Center while at the same time continue to pursue registration of evofosfamide in Japan for the treatment of pancreatic cancer. In addition, we continue to pursue potential collaborations to expand our development pipeline while we complete IND-enabling toxicology studies with TH-3424 with the goal of reaching the clinic with a new compound in 2017", said Barry Selick, Ph.D., chief executive officer of Threshold.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]